Alliance Pharma Regulatory News (APH)

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Capital Markets Event

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will this afternoon host a capital markets event for equity analysts and institutional investors. The event will provide a detailed insight into the Company's prospects following its transformational acquisition of the healthcare products business of Sinclair IS Pharma plc in December 2015.

The capital markets event will take place at the offices of Buchanan, 107 Cheapside, London, EC2V 6DN, and will start at 2.30pm with an introduction by John Dawson, Alliance Pharma's CEO. It will then include presentations on various aspects of Alliance's business from the wider management team.

Analysts and investors who are not already registered to attend the event but who would like to attend please contact Buchanan at the details below.

No new material information will be disclosed at the event.

For further information:

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.